SUMMARY The Randomised Intervention Treatment of Angina (RITA) Trial is a prospective, randomised study to compare the short term and long term effects of percutaneous transluminal coronary angioplasty and coronary artery bypass surgery. During the study a register of patients undergoing coronary arteriography at the fourteen participating centres is being maintained to assess the overall context of patient recruitment. Patients with arteriographically proven coronary artery disease are considered for the trial if the participating cardiologist and surgeon agree that equivalent revascularisation could be achieved by either treatment method. Patients who satisfy the trial entry criteria are randomised to treatment by coronary angioplasty or coronary artery bypass surgery, with prospective stratification into groups with one, two, or three treatment vessels. Randomisation implies an intention to treat the patient by the assigned procedure and the analysis of long term results will include all randomised cases. The trial will recruit at least 1000 patients who will be followed for five years. The major trial end points include death, new myocardial infarction, and new coronary angioplasty or coronary artery bypass procedures. Other outcome measures include symptom and employment status, quality of life, exercise tolerance, and left ventricular function.
Patient selection
The coronary arteriograms of patients who may be eligible for the trial are reviewed by the participating cardiologist and cardiothoracic surgeon at each centre. The surgeon must be prepared to accept the patient for coronary artery surgery and the cardioloHenderson gist must consider that the patient is suitable for coronary angioplasty. Before a patient can be randomised the investigators must jointly identify the major epicardial vessels that require treatment and must agree that equivalent revascularisation could be achieved by either treatment method. Thus the surgeon must prospectively state which vessels he intends to graft ifthe patient is randomised to surgery and the cardiologist must be prepared to attempt dilatation of all important stenoses in the same vessels. Coronary stenoses are regarded as important if there is a reduction in luminal diameter of at least 70% in one angiographic view or a 50% reduction in two views.
The trial does not require that all diseased vessels are treated, but the intention to achieve equivalent revascularisation by either treatment method may include totally occluded vessels. For instance, if a surgeon would graft the distal branches of a proximally occluded artery the cardiologist must be prepared to attempt to reopen the occlusion by coronary angioplasty. It is not necessary for angioplasty to be attempted in a vessel with subclinical lesions even if the surgeon would graft the vessel during a surgical procedure.
Stratification into groups with one, two, or three treatment vessels Patients are prospectively stratified into groups with one, two, or three vessels requiring treatment; patients with more than three treatment vessels are ineligible for randomisation. All treatment vessels must be judged to In addition to these major trial events a range of other outcome measures are recorded. At each follow up assessment, employment and symptom status and performance on an exercise treadmill are documented. The radionuclide ejection fraction is measured one and six months after intervention, and the Nottingham Health Profile is repeated six months after intervention and two years after randomisation.
Other cardiovascular events occurring during follow up, including stroke and hospital admission for unstable angina, are also recorded. In order to evaluate the cost effectiveness of the different treatment policies the duration of all hospital admissions, including admissions to high dependency units, and the details of all repeat coronary arteriograms and repeat intervention procedures are documented.
Ethical considerations
The trial protocol has received ethical approval from the hospital ethics committees of all participating centres. The nature of the trial is explained in detail to all patients who are required to sign a standardised consent form before randomisation. Patients are at liberty to withdraw from the study at any time, although they are encouraged to decline randomisation unless they are prepared to proceed with the assigned intervention procedure.
Statistical considerations
It is intended that at least 1000 patients will be entered in the trial, the primary consideration being a reliable comparison of the rate of new myocardial infarction or death. If in five years there is a 20% incidence of this combined end point in one group, a trial of this size would have 80% power to detect a one third reduction in the incidence in the other group at the 5% significance level. Since the five year fatality rate will probably be lower than 20%, a trial of 1000 patients is likely to be too small to establish or refute that the treatments are equivalent for long term survival. However, 1000 patients will be sufficient to compare other end points such as symptoms, quality of life, exercise performance, and ejection fraction.
Trial organisation
The Randomised Intervention Treatment of Angina Trial comprises fourteen participating centres and a complex management structure including a steering committee of investigators, an executive committee, an ethics committee, and a statistical centre. The steering committee has overall responsibility for the Henderson conduct of the trial, but day to day management is supervised by the executive committee, which also monitors progress at each participating centre. The ethics committee is concerned with the welfare of the patients included in the trial, and is the only committee to which the comparative trial results will be available while the trial is in progress. The statistical centre is responsible for the randomisation of patients, and is maintaining the randomised trial data and the coronary arteriogram register. Each participating centre has employed a research assistant (usually an experienced nurse) to supervise the trial procedures and organise local data collection.
Conclusion
The protocol for the Randomised Intervention Treatment of Angina Trial has been described. The purpose of the study is to compare coronary angioplasty and coronary bypass surgery in suitable patients with coronary artery disease, and this can only reliably be achieved by a randomised clinical trial. Large multicentre clinical trials are difficult to conduct and require a multidisciplinary approach with cooperation across academic and clinical boun- 
